5 Philly Life Sciences Companies We’re Watching in H1 2023

Published on : Published by : Bryan Spiegelberg, Ph.D.

Even as 2023 brings continued economic uncertainty, the Philly life sciences community has much to be optimistic about. Here are five companies whose potential 2023 achievements make them worthy of attention in the first half of the year.

Greater Philadelphia Q4 2022 News Recap – December was a Pivotal Month for Cellicon Valley Companies

Published on : Published by : Alex Keown

Cellicon Valley companies closed out 2022 with a roar. Madrigal Pharmaceuticals announced a breakthrough in NASH that could result in the first-approved drug for that disease. Galera Therapeutics closed out December with plans to seek approval for its severe oral mucositis therapy.

iECURE Snags $65 Million to Support Knock-In Gene Editing Asset for OTC Deficiency

Published on : Published by : Alex Keown

Philadelphia-based iECURE, which is collaborating with Jim Wilson’s Gene Therapy Program (GTP) at University of Pennsylvania, secured $65 million in Series A-1 financing to support its knock-in gene editing therapeutics for liver disorders. Combined with $50 million raised in a previous Series A round, iECURE is well-financed to take its lead asset, GTP-506 into the clinic.